Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNICD4)

• Drug Name: CYT-013-IL1bQb Drug Info
• Synonyms: Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMNICD4

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[3]
Rilonacept	DMGLUQS	Arthritis	FA20	Approved	[4]
Gallium nitrate	DMF9O6B	Hypercalcaemia	5B91.0	Approved	[5]
Canakinumab	DM8HLO5	Autosomal dominant familial periodic fever		Approved	[6]
Diacerein	DMN2Q5I	N. A.	N. A.	Phase 4	[7]
XOMA 052	DMOKQV7	Type-2 diabetes	5A11	Phase 3	[8]
ABT-981	DM6PTIX	Osteoarthritis	FA00-FA05	Phase 2	[9]
AC-201	DMB0TNL	Type-2 diabetes	5A11	Phase 2	[10]
LY-2189102	DMU81BH	Cardiovascular disease	BA00-BE2Z	Phase 2	[11]
TT-301	DM4QV8Y	Alzheimer disease	8A20	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-1 beta (IL1B)	TTRYK0X	IL1B_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00924105) Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
• [3] Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
• [4] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [5] Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
• [8] Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
• [9] Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
• [12] A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.